Recurrent primary biliary cirrhosis: peritransplant factors and ursodeoxycholic acid treatment post-liver transplant (Q33730935)

29 July 2017

title

Recurrent primary biliary cirrhosis: peritransplant factors and ursodeoxycholic acid treatment post-liver transplant (English)

1 reference

primary biliary cholangitis

29 July 2017

0 references

0 references

author name string

Jennifer E Guy

1

1 reference

29 July 2017

Peiqing Qian

2

1 reference

29 July 2017

Jeffrey A Lowell

3

1 reference

29 July 2017

Marion G Peters

4

1 reference

29 July 2017

publication date

1 October 2005

1 reference

29 July 2017

published in

Liver Transplantation

1 reference

29 July 2017

volume

11

1 reference

29 July 2017

issue

10

1 reference

29 July 2017

page(s)

1252-1257

1 reference

Pathogenesis of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune cholangiopathy

29 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050662

Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050662

Prolonged follow-up of patients in the U.S. multicenter trial of ursodeoxycholic acid for primary biliary cirrhosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050662

Recurrent primary biliary cirrhosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050662

HLA and interleukin 1 gene polymorphisms in primary biliary cirrhosis: associations with disease progression and disease susceptibility

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050662

The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050662

Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050662

Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050662

Ursodeoxycholic acid in the treatment of liver diseases

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050662

The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050662

Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050662

Genes within the HLA class II region confer both predisposition and resistance to primary biliary cirrhosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050662

A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050662

Susceptibility to primary biliary cirrhosis is associated with the HLA-DR8-DQB1*0402 haplotype

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050662

Hepatitis C etiology of liver disease is strongly associated with early acute rejection following liver transplantation

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050662

Quality of life in patients with primary biliary cirrhosis

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050662

Biochemical markers of liver fibrosis and lymphocytic piecemeal necrosis in UDCA-treated patients with primary biliary cirrhosis

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050662

Immunosuppression affects the rate of recurrent primary biliary cirrhosis after liver transplantation

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050662

The changing clinical presentation of recurrent primary biliary cirrhosis after liver transplantation

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050662

Recurrence of primary biliary cirrhosis after liver transplantation: Histologic estimate of incidence and natural history

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050662

The effect of immunosuppressive regimens on the recurrence of primary biliary cirrhosis after liver transplantation

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050662

Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050662

Liver transplantation for primary biliary cirrhosis: a long-term pathologic study

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050662

Primary biliary cirrhosis: incidence and predictive factors of cirrhosis development in ursodiol-treated patients

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050662

Benefit of transplantation in primary biliary cirrhosis between 1985-1997.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050662

Transplantation for primary biliary cirrhosis: retrospective analysis of 400 patients in a single center

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050662

Cost-effectiveness of ursodeoxycholic acid therapy in primary biliary cirrhosis.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050662

Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050662

Recurrence of primary biliary cirrhosis after liver transplantation

30 October 2018

1 reference

12 December 2020

Primary biliary cirrhosis: associations with class II major histocompatibility complex antigens

1 reference

12 December 2020

HLA DRw8 and complement C4 deficiency as risk factors in primary biliary cirrhosis

1 reference

12 December 2020

DNA polymorphism of HLA class II genes in primary biliary cirrhosis

1 reference

12 December 2020

Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver

1 reference

12 December 2020

Ursodeoxycholic acid for primary biliary cirrhosis

1 reference

12 December 2020

Immunosuppressive properties of chenodeoxycholic and ursodeoxycholic acids in the mouse

1 reference

12 December 2020

Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis

1 reference

12 December 2020

Quantitative measurement of autoantibodies to recombinant mitochondrial antigens in patients with primary biliary cirrhosis: relationship of levels of autoantibodies to disease progression

1 reference

12 December 2020

Bile acid concentrations in human and rat liver tissue and in hepatocyte nuclei

1 reference

12 December 2020

Time course of histological progression in primary biliary cirrhosis

1 reference

12 December 2020

Molecular aspects of membrane stabilization by ursodeoxycholate [see comment]

1 reference

12 December 2020

Primary biliary cirrhosis. Histological evidence of disease recurrence after liver transplantation

1 reference

12 December 2020

Primary biliary cirrhosis: contribution of HLA class II allele DR8

1 reference

12 December 2020

Identifiers

DOI

10.1002/LT.20511

1 reference

29 July 2017

1 reference

29 July 2017

1 reference